Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? GRACEcast Lung Cancer Video
-
- Science
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
7 min
Top Podcasts In Science
More by GRACEcast
GRACEcast Cancer 101 Video
cancerGRACE - H. Jack West, MD
GRACEcast Head and Neck Cancer Video NEW
cancerGRACE - H. Jack West, MD
GRACEcast Bladder Cancer Video
cancerGRACE - H. Jack West, MD
GRACEcast Cancer 101 Audio
cancerGRACE - H. Jack West, MD
GRACEcast Kidney Cancer Video
cancerGRACE - H. Jack West, MD
GRACEcast Pancreatic Cancer Video
cancerGRACE - H. Jack West, MD